The answer, according to the research team led by Xiaoxu Wang of Nanjing Medical University, is more sobering than many clinicians and patients might hope. After screening 4,553 records from English- and Chinese-language databases, the investigators identified 21 randomized controlled trials conducted across 10 countries, most published between 2020 and 2024, with China contributing the largest share at eight trials. The interventions spanned five broad categories: exercise or rehabilitation programs, nutritional supplementation, multimodal interventions combining both, intensive physiotherapy, and even neuromodulation in the form of transcranial direct current stimulation. When all the evidence was synthesized using Bayesian statistical methods that combine direct and indirect comparisons, the headline finding was stark: for frailty and sarcopenia themselves—the two primary outcomes—no intervention showed a clear advantage over usual care.

That null result for the primary endpoints deserves careful unpacking. Only three trials directly measured frailty, and just two measured sarcopenia, meaning the evidence base for these core conditions was thin to begin with. Seven other objective outcomes also failed to separate the interventions from one another: gait speed, the Timed Up and Go test, the sit-to-stand test, the skeletal muscle index derived from CT imaging, and the six-minute walk distance all showed no statistically significant differences among strategies. The certainty of evidence, graded using the GRADE framework, was rated very low for most of these outcomes. In a field where prehabilitation has been widely promoted as a way to prepare patients for the metabolic trauma of major cancer surgery, the analysis delivers an uncomfortable dose of realism about how little high-quality comparative evidence actually exists.

Yet the picture was not uniformly bleak. Two domains did show signals worth attention. For handgrip strength—a key, reliable marker of both frailty and sarcopenia—prehabilitation exercise ranked highest among the evaluated interventions, with a SUCRA score of roughly 94 percent, and was associated with a modest improvement compared with usual care. The pooled effect corresponded to an increase of approximately 5.4 kilograms of grip strength, which sits close to the minimal clinically important difference of 5.0 to 6.5 kilograms established in older populations. Mechanistically, this makes biological sense: resistance-based training enhances neural drive to muscle through more effective motor-unit recruitment and rate coding, while stimulating muscle protein synthesis via anabolic signaling pathways such as mTOR. Preoperative exercise may also exert anti-inflammatory effects and build physiological reserve before the surgical stress that would otherwise accelerate deconditioning.

The second positive signal emerged for subjective physical function—the patient-reported physical function domains drawn from quality-of-life questionnaires. Here, an enhanced nutritional support pathway and intensive physiotherapy both showed small but statistically significant improvements over standard care, with SUCRA rankings of about 85 percent and 82 percent respectively, and this outcome carried the highest certainty rating in the analysis at moderate. The nutritional pathway, tested in patients undergoing esophagectomy, was notably resource-intensive: it included extended preoperative supplementation with 500 to 1000 milliliters of oral nutritional supplements daily, progressive enteral nutrition through a jejunostomy tube during hospitalization, and thirty days of home enteral nutrition after discharge, with dietitians monitoring adherence by telephone. The authors caution that no trial formally evaluated the cost-effectiveness of this approach, and the staffing and follow-up infrastructure it demands may limit scalability in many healthcare systems.

Perhaps the most intriguing finding came from the subgroup analyses examining when interventions are delivered. For handgrip strength, the benefit was most apparent in the early postoperative period—within the first seven days after surgery—where the effect estimate was stable with zero heterogeneity across studies. Preoperative interventions and those delivered more than a week after surgery showed no clear improvements. The researchers suggest this may reflect the realities of enhanced recovery after surgery pathways: prehabilitation is constrained by the limited window between diagnosis and operation, which restricts training dose and adherence, whereas early postoperative mobilization directly targets the immobility-related deconditioning that occurs during a period of heightened surgical stress and catabolism. In other words, the postoperative signal may reflect both a greater opportunity to counteract acute muscle loss and more consistent delivery of an adequate exercise dose, rather than a true absence of preoperative benefit.

Why do interventions that work reasonably well in healthy older adults appear to lose their punch in gastrointestinal cancer patients? The authors point to cancer-specific pathophysiology as the likely culprit. Gastrointestinal malignancies are frequently complicated by cachexia, systemic inflammation, and treatment-related toxicities that induce a state of anabolic resistance—essentially blunting the muscle’s responsiveness to both exercise stimuli and nutritional support. Cancer-related fatigue further reduces patients’ capacity to engage in and adhere to sufficiently intensive programs. Many of the included trials also failed to reach recommended protein targets; current guidelines advise at least 1.0 gram of protein per kilogram of body weight daily for cancer patients, with many experts advocating 1.2 to 2.0 grams under conditions of metabolic stress, and several studies fell short of these thresholds, potentially limiting any measurable anabolic response.

The study has limitations that temper enthusiasm for even its positive findings. Most of the evidence networks were small and star-shaped, meaning trials compared interventions only against usual care rather than against each other, and formal consistency testing was impossible. Blinding of participants and personnel was rated as high risk in more than 71 percent of studies, raising the possibility of Hawthorne effects, and publication bias could not be formally assessed because fewer than ten studies were available for most outcomes. Adherence rates ranged wildly, from 14 percent to 100 percent, and seven of the 21 trials did not report intervention-related safety data at all—though the events that were reported, including nausea, diarrhea, and muscle discomfort, were mild or transient, with no serious adverse events attributed to the interventions.

The research team lays out a detailed agenda for what must come next. Future trials should enroll at least 256 participants to detect moderate effects with adequate statistical power, treat frailty and sarcopenia as primary endpoints using validated definitions, specify exercise modality, frequency, intensity, and protein targets in replicable detail, and run for at least twelve weeks with follow-up extending to six months. Adherence and adverse events should be reported as core outcomes rather than optional extras, and mechanistic substudies examining inflammatory and metabolic biomarkers could explain why some patients respond while others do not. For now, the authors conclude, the evidence is not yet strong enough to translate into routine clinical recommendations. Prehabilitation exercise may modestly strengthen grip, and structured nutrition pathways may help patients feel more capable—but the larger promise of reversing frailty and sarcopenia in gastrointestinal cancer remains, for the moment, unproven.

Subject of Research: Nonpharmacological interventions for frailty and sarcopenia in older adults with gastrointestinal cancers

Article Title: Nonpharmacological interventions for frailty and sarcopenia in older adults with gastrointestinal cancers: A Bayesian network meta-analysis

Article References: Wang, X., Hui, X., Fu, Z., Guo, Y., Duan, L., Shi, W., Dong, Q., Xu, Q., & Xu, X. (2026). Nonpharmacological interventions for frailty and sarcopenia in older adults with gastrointestinal cancers: A Bayesian network meta-analysis. iScience, 29(10), Article 117257. https://doi.org/10.1016/j.isci.2026.117257

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117257

Keywords: frailty, sarcopenia, gastrointestinal cancer, network meta-analysis, prehabilitation, exercise, nutritional support, handgrip strength, older adults, physical function, cachexia, Bayesian analysis